文献速递系统性红斑狼疮

喜树碱与拓扑替康抑制Fli-1和拓扑异构酶改善狼疮肾炎

Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells.
PubMed 文献 · Arthritis Rheumatol · 2021-06-08

在(NZB × NZW)F1狼疮小鼠中,腹腔注射喜树碱(CPT)1或2 mg/kg、拓扑替康(TPT)0.1或0.3 mg/kg或环磷酰胺可显著延长生存、减轻肾损伤、降低抗dsDNA抗体及肾小球IgG和C3沉积(均P < 0.05)。人肾内皮和系膜细胞经CPT或TPT处理后Fli-1表达下降,IFNα或IFNγ刺激后MCP-1产生减少。提示低剂量CPT和TPT可能重定位用于治疗狼疮肾炎。

要点

  • CPT 1或2 mg/kg及TPT 0.3 mg/kg组40周龄时无蛋白尿>100 mg/dl。
  • CPT、TPT或CYC均显著延长生存并减轻肾损伤(P < 0.05)。
  • CPT或TPT降低人肾细胞Fli-1及IFNα/γ诱导的MCP-1。

核心结论

  • 低剂量喜树碱和拓扑替康可能重定位用于治疗狼疮肾炎。

研究设计与样本

  • 雌性NZBWF1小鼠25周龄起每周两次腹腔注射溶媒、环磷酰胺、CPT(1或2 mg/kg)或TPT(0.03、0.1或0.3 mg/kg),每组8–10只,40周处死评估肾脏病理。
  • 人肾内皮细胞和系膜细胞经CPT或TPT处理,检测细胞因子表达。

主要发现

  • CPT 1或2 mg/kg及TPT 0.3 mg/kg组40周龄时无小鼠蛋白尿>100 mg/dl。
  • TPT 0.1 mg/kg组8只中1只、CYC组10只中1只出现蛋白尿>300 mg/dl,而溶媒组90%小鼠蛋白尿>300 mg/dl。
  • 与溶媒对照相比,CPT 1或2 mg/kg、TPT 0.1或0.3 mg/kg及CYC组生存显著延长、肾损伤减轻、脾肿大减轻、抗dsDNA自身抗体水平降低、肾小球IgG和C3沉积减少(均P < 0.05)。
  • 人肾细胞经CPT或TPT处理后Fli-1表达降低,IFNα或IFNγ刺激后单核细胞趋化蛋白1产生减少。

临床怎么用

  • 动物实验提示低剂量CPT和TPT可能作为狼疮肾炎的候选重定位药物,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli-1 and topoisomerase, on lupus nephritis in (NZB × NZW)F1 (NZBWF1) mice, and to examine the effects of CPT and TPT on inflammatory mediators in human renal cells. METHODS: Female NZBWF1 mice were treated with vehicle, cyclophosphamide (CYC), CPT (1 mg/kg or 2 mg/kg), or TPT (0.03 mg/kg, 0.1 mg/kg, or 0. 3 mg/kg) by intraperitoneal injection twice a week, beginning at the age of 25 weeks (n = 8-10 mice per group). Blood and urine were collected for monitoring autoantibodies and proteinuria. Mice were euthanized at 40 weeks, and renal pathology scores were assessed. Human renal endothelial and mesangial cells were treated with CPT or TPT, and cytokine expression was measured. RESULTS: None of the NZBWF1 mice treated with 1 mg/kg or 2 mg/kg of CPT or 0.3 mg/kg of TPT had proteinuria >100 mg/dl at the age of 40 weeks. One of 8 mice treated with 0.1 mg/kg of TPT and 1 of 10 mice treated with CYC had proteinuria >300 mg/dl, whereas 90% of the mice treated with vehicle had proteinuria >300 mg/dl. Compared to vehicle control, mice treated with 1 mg/kg or 2 mg/kg of CPT, 0.1 mg/kg or 0.3 mg/kg of TPT, or CYC had significantly prolonged survival, attenuated renal injury, diminished splenomegaly, reduced anti-double-stranded DNA autoantibody levels, and reduced IgG and C3 deposits in the glomeruli (all P < 0.05). Human renal cells treated with CPT or TPT had reduced expression of Fli-1 and decreased monocyte chemotactic protein 1 production following stimulation with interferon-α (IFNα) or IFNγ. CONCLUSION: Our findings indicate that low-dose CPT and TPT could be repurposed to treat lupus nephritis.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wang X, Oates JC, Helke KL, et al. Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells. Arthritis Rheumatol. 2021. PMID: 33559345. doi:10.1002/art.41685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。